European Congress of Rheumatology 2023 (EULAR 2023)

Real-world data back CV safety of JAK inhibitors

Audrey Abella, 20230628100000

Two real-world studies presented at EULAR 2023 reflected the cardiovascular (CV) safety of Janus kinase inhibitors (JAKi*) in patients with rheumatoid arthritis (RA).

$Uricase-based combo therapy promising for refractory gout$

Uricase-based combo therapy promising for refractory gout

Elvira Manzano, 20230628000000

Half of gout patients receiving novel uricase analogue infusions, along with a proprietary rapamycin formulation, got their serum urate controlled in two phase III studies presented at EULAR 2023.

SGLT2 inhibitors score big, this time in gout

Elvira Manzano, 20230622000000

Patients initiated on gliflozins or flozins – also called sodium-glucose co-transporter 2 (SGLT2) inhibitors – for type 2 diabetes (T2D) who were previously on metformin had reductions in the incidents of gout of up to 60 percent compared with other second-line agents in a recent study.

Novel drug STRIDES in the right direction for knee OA

Audrey Abella, 20230621100000

In the phase III STRIDES X-Ray Extension study, additional doses of the investigational CLK/DYRK inhibitor lorecivivint delivered favourable outcomes for individuals with advanced knee osteoarthritis (OA).

Dazodalibep reduces Sjögren’s syndrome-related symptoms

Elaine Soliven, 20230621000000

Treatment with dazodalibep, a novel nonantibody fusion protein that acts as an antagonist of CD40 ligand, significantly reduced symptom burden in adults with Sjögren’s syndrome, according to the ALISS trial presented at EULAR 2023.

Romosozumab one-ups denosumab in boosting bone mineral density for chronic steroid users

Jairia Dela Cruz, 20230620140000

In the treatment of chronic glucocorticoid users with high fracture risk, romosozumab yields higher gains in spine bone mineral density (BMD) compared with denosumab, as shown in a pilot trial presented at EULAR 2023.

Artificial intelligence, if used correctly can empower the world of medicine.

AI predicts early-stage rheumatoid arthritis using MRI scans

Stephen Padilla, 20230620120000

It is now possible to predict rheumatoid arthritis (RA), thanks to interpretations of magnetic resonance imaging (MRI) scans made by an artificial intelligence (AI) model.

Abatacept halts RA progression early in high-risk group

Elvira Manzano, 20230620000000

Treatment with abatacept for a year halts disease progression in high-risk patients presenting with signs of imminent onset of rheumatoid arthritis (RA) in the phase IIb APIPPRA trial.

Dual-target oral drug outperforms tofacitinib in RA treatment

Jairia Dela Cruz, 20230619140000

The novel, highly selective dual JAK1/TYK2 inhibitor TLL-018 appears to have better efficacy than the currently approved JAK inhibitor tofacitinib in the treatment of patients with rheumatoid arthritis (RA), according to the results of a head-to-head trial presented at EULAR 2023.

Secukinumab on par with adalimumab biosimilar in r-axSpA

Stephen Padilla, 20230619120000

Treatment with secukinumab (SEC) shows no significant difference with adalimumab biosimilar (SDZ-ADL) in spinal radiographic progression, which remains low over 2 years, among patients with radiographic axial spondyloarthritis (r-axSpA), according to a phase IIIb study presented at EULAR 2023.